ATOPE-PRO, was developed with the intention of consolidating the integration of an innovative system for the prevention of cancer therapy-related cardiovascular toxicity (CTR-CVT) in the continuum care of women with breast cancer in health services. It is a step further towards personalized medicine by optimizing the already available tools and integrating artificial intelligence. Breast cancer survival increases every year, a situation that poses new challenges for health professionals. The European Society for Medical Oncology, a reference in Europe, has just highlighted the need to anticipate to and prevent sequelae derived from the disease and its treatments. This, in addition to having a positive impact on improving the quality of life of people suffering from this disease, would mean a reduction in the risk of recurrence, the appearance of other tumors and other diseases, and death from cancer or other causes, which have a personal impact and represent an overload of the healthcare system. To this end, ATOPE- PRO aims to optimize and refine tools already developed in the previous project (ATOPE, Pl18/01840), integrating artificial intelligence to help identify CTR-CVT, risk profiles, and effective and safe doses (at a clinical level) early on, implementing the program in a longer term, and transferring the results to the social sector (social level). The project has 4 stages: Phase 0 or start-up (to make improvements and analyse usability); Phase 1 for piloting and optimization; Phase 2, to verify efficacy (randomized controlled clinical trial) and Phase 3, in which a deep analysis will be performed and future projects will be conceived.
Recently diagnosed with stage I-III breast cancer
Treatments predisposing to cardiotoxicity (anthracyclines, targeted therapies, radiotherapy)
Signed informed consent form
Medical authorisation to participate
Patient underwent previous cancer treatments.
Patients were previously diagnosed with cancer
Pregnant patients. Patients performing other type of therapeutic exercise at diagnosis time with an intake >or = to 150 moderate-intensity or 75 min of vigorous-intensity a day
Therapeutic exercise practice not recommended because psychiatric or cognitive disorders or cute or chronic condition that prevents exercise (advanced lung disease, oxygen requirement, stenosis >70%, metastasis etc.).
Parallel
Individualised health recommentations
BehavioralIndividualised recommendations for physical activity and exercise, lifestyle, stress management and symptom management with solid scientific evidence established by health organisations and scientific reference committeess through the ATOPE-PRO mobile application based on patients reported status.
General health recommendations
BehavioralRecommendations for physical activity and exercise, lifestyle, stress management and symptom management with solid scientific evidence established by health organisations and scientific reference committeess through the ATOPE-PRO mobile application.
Individualised physical exercise program
BehavioralFollow-up of an individualised exercise program adjusted by daily monitoring of the level of physical, physiological and psychological condition.
Cardiotoxicity
Echocardiography: left ventricular ejection fraction expressed as percentage.
Systolic function
Echocardiography: Strain longitudinal global expressed as percentage.
Number of cardiovascular events
Clinical records registration expressed as number (N) of cardiovascular events.
Comorbidities
Any chronic pathological condition different from the oncologic one will be registed by a clinical interview, an expressed in results as number (N) and type.
Heart rate variability
Assessment of cardiac autonomic system balance by a Holter registration, registering the log-transformed root mean square of successive R-R intervals (lnRMSSD) and expressed as milliseconds (ms).
Heart rate
Resting heart rate registration by a Holter, expressed as beats per minute (bpm).
Click on the lead sponsor to view all of their trials.
Universidad de Granada
Lead sponsor
Instituto de Salud Carlos III
Collaborator
Hospital Clinico Universitario San Cecilio
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
